Clinical Trial Update: Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease [Phase 3]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 3 switch-over study of a biosimilar agalsidase beta for Fabry disease, with results posted on 2026-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• Biosimilar agalsidase beta (agalsidase beta)

Snippet

Sponsor: Bio Sidus SA | Conditions: Fabry Disease | Phase 3 | Status: COMPLETED | Results posted: 2026-02-18